Servier Bio-innovation Llc

This study tested a new drug called S227928, alone or with another drug (venetoclax), in 13 people with blood cancers that had come back or stopped responding to treatment. The goal was to find a safe dose and see if it could shrink the cancer. The trial was stopped early, so res…

This early-stage trial tested a combination of ivosidenib (a targeted drug) with two immunotherapy drugs (nivolumab and ipilimumab) in people with advanced bile duct cancer that has a specific IDH1 gene mutation. The study was stopped by the sponsor before the expansion phase, so…